跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 643 条关于
“Tardive Dyskinesia”
全部
643
临床试验
497
药物
13
机构
5
资讯
128
10个月前
Neurocrine Review Reveals Key Differences Between FDA-Approved Tardive Dyskinesia Treatments
去年
Serina Therapeutics Advances Once-Weekly Injectable VMAT2 Inhibitor for Tardive Dyskinesia Treatment
12个月前
Real-World Data Show AUSTEDO XR Delivers High Patient Satisfaction and Movement Improvement in Tardive Dyskinesia
2个月前
Tardive Dyskinesia Market Projected to Reach USD 4.4 Billion by 2036, Growing at 8.1% CAGR Amid Pipeline Innovation
去年
Phase 4 KINECT-PRO Trial Shows Ingrezza Significantly Improves Quality of Life in Tardive Dyskinesia Patients
4个月前
IMPACT-TD Registry Reveals Stark Diagnostic Gap: Only 23% of Young Adults with Mood Disorders and Tardive Dyskinesia Symptoms Receive Formal Diagnosis
去年
Luye Pharma Launches Phase II Trial of LY03015 for Tardive Dyskinesia and Huntington's Disease
8个月前
INGREZZA Demonstrates Nearly Two-Fold Higher VMAT2 Target Occupancy Than AUSTEDO XR in Head-to-Head Study
9个月前
Neurocrine's Phase 3 Valbenazine Trial for Dyskinetic Cerebral Palsy Fails to Meet Primary Endpoints
去年
Evoke Pharma Secures Patent Extension for GIMOTI Nasal Spray, Extending Market Exclusivity to 2036
第 1 页,共 13 页
上一页
下一页